Cerity Partners LLC grew its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 116.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,881 shares of the company's stock after purchasing an additional 15,563 shares during the quarter. Cerity Partners LLC's holdings in Progyny were worth $645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. Natixis bought a new position in Progyny during the fourth quarter valued at $69,000. Covestor Ltd lifted its position in Progyny by 69.4% during the fourth quarter. Covestor Ltd now owns 6,868 shares of the company's stock valued at $118,000 after purchasing an additional 2,814 shares during the last quarter. GAMMA Investing LLC lifted its position in Progyny by 233.9% during the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock valued at $120,000 after purchasing an additional 3,768 shares during the last quarter. State of Wyoming lifted its position in Progyny by 98.2% during the fourth quarter. State of Wyoming now owns 12,376 shares of the company's stock valued at $213,000 after purchasing an additional 6,132 shares during the last quarter. Finally, Quantessence Capital LLC bought a new position in Progyny during the fourth quarter valued at $243,000. 94.93% of the stock is currently owned by institutional investors.
Progyny Stock Performance
Shares of PGNY traded up $0.11 during mid-day trading on Friday, hitting $23.11. 891,727 shares of the company's stock were exchanged, compared to its average volume of 1,108,830. The company has a market cap of $1.98 billion, a price-to-earnings ratio of 40.54, a P/E/G ratio of 2.31 and a beta of 1.31. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $29.65. The stock's 50-day moving average is $21.92 and its 200-day moving average is $21.96.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a net margin of 4.33% and a return on equity of 10.90%. The firm had revenue of $324.04 million during the quarter, compared to analyst estimates of $307.86 million. During the same period last year, the business earned $0.17 EPS. The firm's revenue was up 16.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on PGNY shares. Truist Financial increased their target price on shares of Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Canaccord Genuity Group reduced their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Leerink Partnrs raised shares of Progyny from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 8th. Finally, Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target on the stock in a research note on Tuesday, July 8th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Progyny currently has an average rating of "Moderate Buy" and an average target price of $24.82.
Read Our Latest Stock Analysis on PGNY
Insider Activity
In other news, Director Cheryl Scott sold 2,675 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director directly owned 14,112 shares in the company, valued at approximately $311,451.84. This trade represents a 15.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.40% of the company's stock.
Progyny Profile
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Stories
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
